Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Revenue Recognition and Contractual Adjustments - Contract Assets and Liabilities (Details)

v3.19.1
Revenue Recognition and Contractual Adjustments - Contract Assets and Liabilities (Details) - USD ($)
$ in Thousands
Mar. 31, 2019
Dec. 31, 2018
Contract with Customer, Asset, Net [Abstract]    
Current pharma contract asset $ 192 $ 86
Long-term pharma contract asset 417 268
Total pharma contract asset 609 354
Capitalized Contract Cost [Abstract]    
Current pharma capitalized commissions 310 271
Long-term pharma capitalized commissions 766 650
Total pharma capitalized commissions 1,076 921
Contract with Customer, Liability [Abstract]    
Current pharma contract liability 1,017 927
Long-term pharma contract liability 1,935 1,652
Total pharma contract liability $ 2,952 $ 2,579